Gavreto (pralsetinib) is tyrosine kinase inhibitor and is used as an antineoplastic agent.
Gavreto is a prescription medicine used to treat non-small cell lung cancer that has spread to other parts of the body (metastatic).
Gavreto is used only if your cancer has a specific genetic marker (an abnormal "RET" gene fusion). Your doctor will test you for this gene fusion.
Gavreto was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, some people responded to this medicine, but further studies are needed.
